Everlab raises $15m VC funding to make more Aussies live longer and become ‘superhuman’

The Melbourne start-up has completed the raise to accelerate its plans to deliver preventive care and longevity solutions to the masses, rewriting the script on chronic disease.

Everlab CEO Marc Hermann, chief product officer Anshul Jain, chief medical officer Dr Steven Lu and chief operations officer Sam Kothari want to bring their preventive healthcare to the masses.

Marc Hermann isn’t joking when he says he’s German so naturally efficient after he raised $15m to expand his network of longevity clinics across Australia and beyond to make more people healthier.

Mr Hermann, founder and chief executive of Melbourne-based Everlab, charges $3000 for a “flagship” assessment of one’s health, providing a “50-year personalised health road map”. He has fused traditional GP clinics with the latest diagnostics and artificial intelligence to make preventive healthcare more affordable and help more people live longer.

But with the current price for Everlab’s services, it is currently viewed as a luxury. That hasn’t stopped people lining up, with the company having a waiting list in the tens of thousands and as the longevity craze grips Australia and the world.

Still, the notion of being exclusive and luxurious is a perception that Mr Hermann is desperately seeking to shake off.

“We believe everyone deserves access to world-class preventive care,” he said.

“By combining AI with the knowledge of leading clinicians, we’ve built a new kind of health platform designed to deliver smarter, earlier care to millions. Our goal is really not to build up a luxury, exclusive service. Our plan is really to make it accessible to the mass market consumer over time.

“And the way we’re going to do it is via tech at scale. We’re developing our own AI models right now and the output is very impressive.”

The $15m raise, which global venture capital firm Left Lane Capital led, aims to accelerate those plans.

And there is a pressing need. An ageing population means people are living longer but in poorer health, while chronic diseases are responsible for more than 70 per cent of global deaths.

Chronic diseases are responsible for 70 per cent of global deaths.

Everlab currently has clinics in Melbourne, Sydney, Brisbane and Perth and on track to deliver 20 times growth this year. It plans to open another clinic in Adelaide before moving to New Zealand, then the US or Europe.

“Maybe it’s the German in me, we’ve been very capital efficient to data, so with the amount of money we have raised, that gives us quite a bit of runway.

“We have been actually limited by the capacity we have. So having enough doctors, having enough testing sites. We only have been able to service a little bit more than, like, 2000 customers to date.

“With this cap raise, where most of the money will go is really building out that supply, and also really ensuring that also with 10,000, 100,000 people, the quality of the service and the level of personalisation stays the same.”

Spending cash efficiently is essential in healthcare. “Doctors are, unfortunately, very expensive humans,” Mr Hermann said.

“They take a very long time to train up and if they’re great doctors, they can charge a certain price.”

A patient at one of Everlab's clinic measure's their VO2 fitness levels.

On that score, he said charging $3000 for Everlab’s flagship is relatively affordable, considering it involves “head-to-toe” diagnostics, including advanced blood biomarkers, heart health assessment, DEXA scan, physical and nutrition assessments and six-month retesting.

“For us to be able to offer that service for three grand is, I would say, like a pretty big win. And the way we did that is really through the tech we have built.”

But Mr Hermann acknowledges that $3000 is still expensive for many people, and reiterates his goal to make it more accessible. This includes a new $1200 entry level product.

“We found a way to consolidate around 80 per cent of the last 30 years worth of medical data in Australia for all members. So if you’re a regular doctor who would want to do what we’re doing, we would have to ping each individual provider, get the data, clean up the data … then research the ranges for this particular person and get to a conclusion.

“We basically built an AI system that automatically gets all of the data, cleans it, pushes it into our platform, visualises it, and applies personalised reference ranges.”

Everlab provides “head-to-toe” diagnostics, including advanced blood biomarkers, heart health assessment, DEXA scan, physical and nutrition assessments and six-month retesting.

Everlab has developed a suite of AI agents that ingest, analyse, and interpret complex health data. These agents automate clinical summaries, identify early risk markers, and recommend personalised next steps, freeing physicians from administrative overhead and enabling earlier, more precise interventions.

For example, Mr Hermann says, two of Everlab’s co-founders are of Indian heritage, with “by nature of ethnicity have a higher risk of heart disease”.

“So if they go out, get tested in the wrong suburb, they’re actually getting compared to the wrong reference range, because the reference range is usually the reference range of a particular lab.

“The danger might never get flagged. We did that whole work to streamline the effort here. We decreased the time needed from probably 15-20, hours down to like minutes because the doctor basically gets the data there and can then apply some level of qualitative judgment.”

Everlab founder and chief executive Marc Hermann doesn't want to the company's longevity services to be exclusive or luxurious.

To date, Everlab has processed over 1,000,000 biomarkers through full-body health testing.

But Mr Hermann said alarmingly, one in four test results are abnormal, uncovering serious conditions such as blocked arteries, gastrointestinal tumours, early-stage cancers, and congenital brain abnormalities.

“We were surprised ourselves, and didn’t expect that number to be that high. The cost of chronic disease worldwide is just incredibly high. I think it’s like one of the biggest problems of our time.

“We live longer than ever before, but we also spent the longest time in poor health. So for us, we really want to flip the script, and move from a sick care model to proactive care.”

He highlights heart disease – the biggest killer in Australia and most Western nations – as an example.

“The frightening stat is that 75 per cent of heart attacks happen in people with normal cholesterol levels, so people are just not aware that they are at risk.

“If you look at the different scans we have been doing, these are exactly the cases where we do find blocked arteries, which does not mean that the person you know would have a heart attack tomorrow, but usually that means your risk in two to five years is very, very high.

“It’s then really understanding what are the right steps we can take to prevent that from happening.”

Laura Sillman, principal at Left Lane Capital, said: “Preventive care has always been a medical ideal but rarely a commercial reality”.

“Everlab has built a product and model that makes it scalable, combining clinical depth with software leverage and operational precision. We’re excited to support them as they build a category-defining platform.”

The $15m raise follows Everlab securing $3m from investors, including European VC fund b2venture, Ten13, AfterWork and Flying Fox, in late 2023

Originally published as Everlab raises $15m VC funding to make more Aussies live longer and become ‘superhuman’